We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-14.64%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.19B
AUM Growth
-$126M
Cap. Flow
+$122M
Cap. Flow %
10.23%
Top 10 Hldgs %
29.08%
Holding
134
New
12
Increased
77
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.7M
2
WBA
Walgreens Boots Alliance
WBA
+$9.86M
3
ALKS icon
Alkermes
ALKS
+$7.68M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.42M
5
RDUS
Radius Health, Inc.
RDUS
+$7.3M

Top Sells

Rank Stock Value
1
IDXX icon
Idexx Laboratories
IDXX
+$9.3M
2
RLYP
RELYPSA INC COM
RLYP
+$7.14M
3
ABBV icon
AbbVie
ABBV
+$5.18M
4
DYAX
DYAX CORPORATION
DYAX
+$4.67M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 77.87%
2 Financials 3.87%
3 Industrials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRGA
51
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$7.44M 0.62%
62,000
– –
COO icon
52
Cooper Companies
COO
$14.5B
$7.33M 0.61%
190,400
+14,400
+8% +$497K
EPZM
53
DELISTED
Epizyme, Inc
EPZM
$7.14M 0.6%
589,000
+219,000
+59% +$2.21M
TVTX icon
54
Travere Therapeutics
TVTX
$5.78B
$7.12M 0.6%
521,400
-153,600
-23% -$2.33M
MCRB icon
55
Seres Therapeutics
MCRB
$48.9M
$6.96M 0.58%
13,100
+830
+7% +$433K
EW icon
56
Edwards Lifesciences
EW
$51.7B
$6.7M 0.56%
+228,000
New +$6.29M
VRTX icon
57
Vertex Pharmaceuticals
VRTX
$126B
$6.67M 0.56%
83,900
+11,150
+15% +$1.01M
ALKS icon
58
Alkermes
ALKS
$8.25B
$6.65M 0.56%
+194,500
New +$7.68M
CRVS icon
59
Corvus Pharmaceuticals
CRVS
$1.17B
$6.63M 0.56%
+456,887
New +$6.56M
ONC
60
BeOne Medicines Ltd
ONC
$39.4B
$6.59M 0.55%
+225,000
New +$6.37M
XENT
61
DELISTED
Intersect ENT, Inc
XENT
$6.46M 0.54%
340,000
+2,707
+0.8% +$49K
ATHN
62
DELISTED
Athenahealth, Inc.
ATHN
$6.35M 0.53%
45,750
+6,250
+16% +$857K
ADAP
63
DELISTED
Adaptimmune Therapeutics
ADAP
$6.22M 0.52%
765,001
– –
NVDQ
64
DELISTED
Novadaq Technologies Inc.
NVDQ
$6.16M 0.52%
555,000
+15,000
+3% +$159K
HTWR
65
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$6.06M 0.51%
193,000
+32,331
+20% +$1.09M
DERM
66
DELISTED
Dermira, Inc.
DERM
$6M 0.5%
290,000
– –
CHRS icon
67
Coherus Oncology
CHRS
$196M
$5.99M 0.5%
282,000
– –
REGN icon
68
Regeneron Pharmaceuticals
REGN
$80.8B
$5.95M 0.5%
16,500
+5,500
+50% +$2.27M
FPRX
69
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5.87M 0.49%
144,500
+9,500
+7% +$327K
INSY
70
DELISTED
Insys Therapeutics, Inc.
INSY
$5.84M 0.49%
365,500
+27,000
+8% +$513K
INSM icon
71
Insmed
INSM
$28.6B
$5.7M 0.48%
450,000
+17,500
+4% +$230K
EVHC
72
DELISTED
Envision Healthcare Holdings Inc
EVHC
$5.43M 0.45%
88,844
+7,014
+9% +$461K
CO
73
DELISTED
Global Cord Blood Corporation
CO
$5.34M 0.45%
880,000
– –
KDNY
74
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$5.32M 0.45%
83,000
– –
ITCI
75
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.21M 0.44%
187,500
+7,500
+4% +$250K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rock Springs Capital Management held 134 positions worth $1.19B, down 9.6% from $1.32B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $122M of net new capital in Q1 2016, opening 12 new positions and adding to 77 existing holdings. Its largest new stake was Bristol-Myers Squibb: 170,000 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $2.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2016 buy was Bristol-Myers Squibb: 170,000 shares worth $10.9M.
  • Rock Springs Capital Management added most to ANACOR PHARMACEUTICALS INC COM in Q1 2016, an estimated $7.42M increase.
  • Rock Springs Capital Management's biggest Q1 2016 reduction was Travere Therapeutics, cutting an estimated $2.33M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q1 2016, selling an estimated $9.3M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.19B portfolio in Q1 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 6 in Q1 2016.
  • Rock Springs Capital Management's portfolio value fell 9.6% quarter-over-quarter to $1.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2016, filed 16 May 2016.